Biofil Chemicals and Pharmaceuticals Limited (BOM:524396)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Pharma Division	189.63M	266.60M	278.68M	-	190.05M
Pharma Division Growth	-28.87%	-4.33%	-	-	-30.00%
Chemical Division	94.32M	67.42M	121.67M	-	33.77M
Chemical Division Growth	39.90%	-44.59%	-	-	-64.07%
Total	283.95M	334.02M	400.35M	-	223.82M
Total Growth	-14.99%	-16.57%	-	-	-38.76%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
India	314.78M	335.82M	404.09M	300.35M	223.82M
India Growth	-6.27%	-16.89%	34.54%	34.19%	-37.50%
Total	314.78M	335.82M	404.09M	300.35M	223.82M
Total Growth	-6.27%	-16.89%	34.54%	34.19%	-37.50%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 16, 2026

Data Sources Report a data error